WVE NASDAQ
Wave Life Sciences Ltd.
1W: +0.9%
1M: -6.0%
3M: -40.6%
YTD: -78.4%
1Y: -51.6%
3Y: -37.4%
5Y: -26.4%
$3.45
+0.24 (+7.48%)
Weekly Expected Move ±7.7%
$3
$3
$3
$3
$4
Credit Risk of going bust: higher than 79% of companies Debt: 6.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 99%), Wave Life Sciences Ltd. would be worth roughly what it owes.
Total debt $43.3M against a stock market value of $680.4M.
Distance to default 2.65 (Merton model): prices to 2026-10-27, balance sheet 2026-09-30, debt counted $23.8M (short-term plus half of long-term), stock volatility 111.1%; Altman Z'' -56.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.05 (down 99%), Wave Life Sciences Ltd. would be worth roughly what it owes.
Total debt $43.3M against a stock market value of $680.4M.
Distance to default 2.65 (Merton model): prices to 2026-10-27, balance sheet 2026-09-30, debt counted $23.8M (short-term plus half of long-term), stock volatility 111.1%; Altman Z'' -56.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-10-18
Earliest Filing
2023-12-08
Latest Filing
partner: 4
investor: 2
Counterparties (Filed by WVE)
6 relationshipsCompanies named in WVE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| GSK | GLAXF | partner | Collaboration partner for WVE-006 development and commercialization | 2023-12-08 | View |
| Glaxo Group Limited | — | investor | Investor in Wave Life Sciences Ltd. equity issuance | 2023-01-30 | View |
| GlaxoSmithKline Intellectual Property (No. 3) Limited | — | partner | Counterparty to Collaboration and License Agreement | 2023-01-30 | View |
| GlaxoSmithKline Intellectual Property (No. 3) | — | partner | Entered into a Collaboration and License Agreement for oligonucleotide therapeutics research and development | 2022-12-13 | View |
| Glaxo Group Limited | — | investor | Purchased ordinary shares in an equity investment and entered into an investor agreement | 2022-12-13 | View |
| Takeda Pharmaceutical Company Limited | TKPHF | partner | Amendment to Collaboration and License Agreement for CNS disorder programs | 2021-10-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-27 | Earnings Release; Exhibits | View | |
| 2026-08-07 | Material Agreement; Unregistered Equity Sales; Change in Control; Officer/Director Change; Bylaws Am | Agreement | View |
| 2026-07-30 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-26 | Shareholder Vote | View | |
| 2026-05-18 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-28 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-21 | Other Events; Exhibits | View | |
| 2026-04-15 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-03-26 | Regulation FD; Other Events; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-02 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-11 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen | Agreement | View |
| 2025-12-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-17 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-30 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-24 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-03 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR